Screening of Auto-antigens as Diagnostic Biomarkers in Sera of Patients with Cholangiocarcinoma by SERPA Technique

Authors

  • Urwa Tanveer Allied Burn and Reconstructive Surgery Center, Faisalabad, Pakistan.
  • Hafsa Tariq Services Institute of Medical Sciences, Lahore, Pakistan
  • Nargis Haider Kakar Department of Physiology, Bolan University of Medical and Health Sciences, Quetta, Pakistan.
  • Tariq. M. Tahir Department of Pathology, Independent Medical College, Faisalabad, Pakistan.
  • Qurat-ul-ain Fatima Physiology Department, Pak Red Crescent Medical College, Dina Nath, Kasur, Pakistan
  • Hina Sadaf Department of Physiology, Avicenna Medical College, Lahore, Pakistan.
  • Taimoor Anwar Department of Neurosurgery, Allied Hospital, Faisalabad, Pakistan.

DOI:

https://doi.org/10.31580/pjmls.v1i1.983

Keywords:

Biomarkers, SERPA, Cholangiocarcinoma

Abstract

Cholangiocarcinoma (CC) is one of the main crucial hepatic malignancies; hence CC is the prime cause for cancer death occurred due to bile duct cancer. A wide range of studies showed that the expression of intracellular proteins associated with the progression of tumor process might be a response of autoantibody. Unlike intracellular components, autoantibodies can appear in cancer patients long before clinical appearance of the cancer. Apparently, CC autoantibodies can appear at any point in the transformation of chronic liver disease; those autoantibodies may not apparent in erstwhile non-transformation phases, lead to a significant increase in the quantity of patients with CC positive for the presence of autoantibodies. The aim of present study was to detect the cellular proteins involved in bile duct cancer process by the use of immunoblotting technique and to predict the future biomarkers of CC. SERPA technique was applied to detect the differentially expressed proteins from nine CC patients’ sera adopting standard protocol. 2-D maps revealed a number of protein spots after gels staining. Proteins of interest were observed between pH 5 and pH8 having molecular mass range between 20 and 90 kDa. Comparative analysis of blots indicated four common immunoreactive spots in CCSW1 cell lines. These cancer specific proteins might be used for CC diagnosis at early stage.

 

 

References

1. Hill-Baskin A, Markiewski M, Buchner D, Shao H, Desantis D, Hsiao G, Subramaniam S, Berger N, Croniger C, Lambris J, Nadeau J. Diet-induced hepatocellular carcinoma in genetically-predisposed mice. Hum Mol Genet. 2009;18(16):2975-88.

2. Sakamoto M. Early HCC: Diagnosis and molecular markers. J Gastroenterol. 2009;44Suppl 19:108-11.

3. Li C, Tan YX, Zhou H, Ding SJ, Ma DJ. Proteomic analysis of Hepatitis B virus associated Hepatocellular carcinoma: Identification of potential tumour markers. Proteomics. 2005;5:1125-39.

4. Lim S, Park S, Kim W, Park SG, Kim HA. Proteome Analysis of Hpatocellular Carcinoma. Biochim, Biophys. Resear commun. 2002;291:1031-7.

5. Troeles Z, Harcha HC, Mads G, Anirban M, Akhilesh P. Differential membrane proteomics using O-labeling to identify biomarkers for Cholangiocarcinoma . J. Proteomics Res. 2008;11:4670-77.

6. Khan S, Thomas H, Davidson B, Taylor-Robinson S. Cholangiocarcinoma. Lancet. 2005;366(9493):1303-14.

7. Reddy S, Patel T, Current approach and to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenenterol Rep. 2006;8:30-37.

8. Yalcin S. Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology. 2004;51:43-50.

9. Scarlett C, Saxby A, Nielsen A, Bell C, Samra J, Hugh T, Baxter R, Smith Rc. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile ductstricture. Hepatology. 2006;44:658-66.

10. Looi K, Nakayasu E, Diaz R, Tan E, Almeida I, Zhang J. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008;7:4004-12.

11. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EKL, Tan EM. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol. 2001;125(1):3–9.

12. Scott DI. Immunoblotting and dot blotting. J Immunol Methods 1989 ; 119 : 15387.

13. Jisnuson S, Chantragan S, Pantipa S, Siriporn K. Proteomics profiling of cholangiocarcinoma cell line treated with pomiferin from derris malaccensis. PROTEOMICS. 2005;5: 4504-4509.

14. Soussi T. P 53 Antibodies in the sera of patients varius types of cancers: a review. Cancer RES 2000;60:1777-88.

Downloads

Published

2019-09-22